Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Cancer Letters
|
March 18, 2018
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer
Patricia Fernández-Nogueira, Aleix Noguera-Castells, Gemma Fuster, et al.
Journal of Cellular Physiology
|
April 22, 2008
Netrin-1 can affect morphogenesis and differentiation of the mouse mammary gland
Luigi Strizzi, Mario Mancino, Caterina Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
Identification of cripto-1 as a novel serologic marker for breast and colon cancer
Caterina Bianco, Luigi Strizzi, Mario Mancino, et al.
Cancer Research
|
September 14, 2013
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer
Susana Garcia-Recio, Gemma Fuster, Patricia Fernandez-Nogueira, et al.
Breast Cancer Research and Treatment
|
March 8, 2024
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
María Gion, Juan José García-Mosquera, José Manuel Pérez-García, et al.
Breast Cancer Research : BCR
|
July 6, 2018
Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis
Arantzazu Zubeldia-Plazaola, Leire Recalde-Percaz, Núria Moragas, et al.
NPJ Breast Cancer
|
June 20, 2025
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
Joan Albanell, Angelo Gámez Pozo, Carlos L Arteaga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2019
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Patricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, et al.
The Lancet. Oncology
|
October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Thorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Cancer Letters
|
March 18, 2018
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer
Patricia Fernández-Nogueira, Aleix Noguera-Castells, Gemma Fuster, et al.
Journal of Cellular Physiology
|
April 22, 2008
Netrin-1 can affect morphogenesis and differentiation of the mouse mammary gland
Luigi Strizzi, Mario Mancino, Caterina Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
Identification of cripto-1 as a novel serologic marker for breast and colon cancer
Caterina Bianco, Luigi Strizzi, Mario Mancino, et al.
Cancer Research
|
September 14, 2013
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer
Susana Garcia-Recio, Gemma Fuster, Patricia Fernandez-Nogueira, et al.
Breast Cancer Research and Treatment
|
March 8, 2024
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
María Gion, Juan José García-Mosquera, José Manuel Pérez-García, et al.
Breast Cancer Research : BCR
|
July 6, 2018
Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis
Arantzazu Zubeldia-Plazaola, Leire Recalde-Percaz, Núria Moragas, et al.
NPJ Breast Cancer
|
June 20, 2025
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
Joan Albanell, Angelo Gámez Pozo, Carlos L Arteaga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2019
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Patricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, et al.
The Lancet. Oncology
|
October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Thorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Page
of 4